# Johnson & Johnson (JNJ) Stock Rises on Strong Q3 Performance and Upbeat Outlook

In this insightful podcast episode, we analyze Johnson & Johnson's current market position as its stock trades at approximately $194 per share, showing steady momentum with a modest 1% gain in recent trading. We dive deep into JNJ's impressive Q3 results, where the healthcare giant exceeded expectations with $2.80 earnings per share and nearly 7% organic sales growth, leading management to raise their 2025 revenue guidance.

The episode explores how standout performers like Darzalex and Tremfya are successfully offsetting revenue challenges from Stelara's patent expiration, while the MedTech segment continues to thrive with new product launches. We examine analyst sentiment, which remains predominantly positive with a consensus "buy" rating and a $196 price target, though some experts anticipate short-term consolidation between $192-$199 before potentially breaking the $200 barrier.

For investors seeking stable blue-chip investments, we discuss JNJ's attractive valuation metrics, including its P/E ratio near 19 and dividend yield approaching 3%, along with the company's promising growth projections for 2026 driven by innovative medicines and MedTech advancements.

Listen now to gain valuable insights into one of healthcare's most reliable performers and what its recent performance signals for long-term investors.

#JohnsonAndJohnson #StockAnalysis #InvestmentStrategy #HealthcareStocks #DividendStocks #Q3Earnings #MedTech

For more http://www.quietplease.ai

Stock up on these deals
https://amzn.to/3QFpYIX

This content was created in partnership and with the help of Artificial Intelligence AI